These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30630670)

  • 1. Framework for assessing pharmacy value.
    Urick BY; Urmie JM
    Res Social Adm Pharm; 2019 Nov; 15(11):1326-1337. PubMed ID: 30630670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration.
    Richard C; Urick BY; Pathak S; Jackson J; Livet M
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1568-1578. PubMed ID: 34714107
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons Learned from Using Global Outcome Measures to Assess Community Pharmacy Performance.
    Urick BY; Ferreri SP; Shasky C; Pfeiffenberger T; Trygstad T; Farley JF
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1278-1283. PubMed ID: 30479196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance-based pharmacy payment models: the case for change.
    Jackson J; Urick B
    Aust Health Rev; 2019 Oct; 43(5):502-507. PubMed ID: 31505158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conceptual framework for evaluation of community pharmacy pay-for-performance programs.
    Harrington A; Malone D; Doucette W; Vaffis S; Bhattacharjee S; Chan C; Warholak T
    J Am Pharm Assoc (2003); 2021; 61(6):804-812. PubMed ID: 34413002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and effect of performance-based pharmacy payment models.
    Urick BY; Pathak S; Hughes TD; Ferreri SP
    J Manag Care Spec Pharm; 2021 Mar; 27(3):306-315. PubMed ID: 33645246
    [No Abstract]   [Full Text] [Related]  

  • 7. Forging a novel provider and payer partnership in Wisconsin to compensate pharmacists for quality-driven pharmacy and medication therapy management services.
    Trapskin K; Johnson C; Cory P; Sorum S; Decker C
    J Am Pharm Assoc (2003); 2009; 49(5):642-51. PubMed ID: 19748873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of financial outcomes under a value-based payment program for community pharmacies.
    Doucette WR; DeVolder R; Heggen T
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1198-1208. PubMed ID: 34464212
    [No Abstract]   [Full Text] [Related]  

  • 9. Community pharmacy owners' views of star ratings and performance measurement: In-depth interviews.
    Teeter BS; Fox BI; Garza KB; Harris SG; Nau DP; Owensby JK; Westrick SC
    J Am Pharm Assoc (2003); 2016; 56(5):549-54. PubMed ID: 27521167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of financial incentives on the quality of health care provided by primary care physicians.
    Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and reliability assessment of a tool to assess community pharmacist potential to influence prescriber performance on quality measures.
    Nelson M; Pickering M; Holland L; Urick B; Campbell P
    J Am Pharm Assoc (2003); 2020; 60(6):e200-e204. PubMed ID: 32800457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality.
    Academy of Managed Care Pharmacy ; American Pharmacists Association
    J Am Pharm Assoc (2003); 2014; 54(3):228-40. PubMed ID: 24770440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulated patients in the community pharmacy setting. Using simulated patients to measure practice in the community pharmacy setting.
    Watson MC; Skelton JR; Bond CM; Croft P; Wiskin CM; Grimshaw JM; Mollison J
    Pharm World Sci; 2004 Feb; 26(1):32-7. PubMed ID: 15018257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a reimbursed medication review program: Corporate and pharmacy level strategies.
    MacKeigan LD; Ijaz N; Bojarski EA; Dolovich L
    Res Social Adm Pharm; 2017; 13(5):947-958. PubMed ID: 28462792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market dynamics of community pharmacies in Minnesota, U.S. from 1992 through 2012.
    Schommer JC; Yusuf AA; Hadsall RS
    Res Social Adm Pharm; 2014; 10(1):217-31. PubMed ID: 23669250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Merit-Based Incentive Payment System: Meaningful Changes in the Final Rule Brings Cautious Optimism.
    Manchikanti L; Helm Ii S; Calodney AK; Hirsch JA
    Pain Physician; 2017; 20(1):E1-E12. PubMed ID: 28072793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Membership Pharmacy Model: Initial impact and feasibility.
    Hohmeier KC; Baker P; Storey C; Martin N; Gatwood JD
    J Am Pharm Assoc (2003); 2023; 63(2):672-680.e1. PubMed ID: 36564328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacy characteristics correlating to performance in a community pharmacy network.
    Renfro CP; Urick BY; Mansour MA; Ferreri SP
    J Am Pharm Assoc (2003); 2019; 59(2):275-279. PubMed ID: 30827530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.